Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

USP Reaches Agreements with China

By Drug Discovery Trends Editor | June 22, 2009

As part of its efforts to improve the quality of medicines and food ingredients worldwide, the U.S. Pharmacopeial (USP) Convention this week reached three new cooperative agreements with Chinese drug control authorities. Because Chinese manufacturers supply so much of the world’s drug and food ingredients, these agreements—coupled with three previous agreements between USP and other government organizations in China—mark a significant commitment to ensure that concerns about quality are addressed. USP is a scientific, nonprofit organization that sets standards for the quality of prescription and over-the-counter drugs that are enforced by the U.S. Food and Drug Administration (FDA) in the United States. USP also sets standards for the quality of food ingredients and dietary supplements; these and USP’s drug standards are used in more than 130 countries.

At a June 18 ceremony in Guangzhou, China, where he signed a Memorandum of Understanding (MOU) with the Guangzhou Municipal Institute of Drug Control, Roger L. Williams, M.D., USP’s chief executive officer, said, “I am impressed at the energy and commitment of the Chinese people as they work to bring good quality medicines to consumers and patients in China and around the world. We are united in that goal.” Mr. Yingqiao Jiang, head of the Guangzhou Institute, observed, “Chinese manufacturers share that commitment with regulatory bodies such as the Guangzhou Institute and organizations like USP. We are pleased to work together to help ensure the quality of medicines and their ingredients.”

Earlier this week, USP also signed MOUs with the Beijing Municipal Institute of Drug Control and the Zhejiang Institute for Food and Drug Control. All are focused on strengthening the relationships through such initiatives as scientist exchange programs, joint standards- and testing-related work, and other projects to improve drug quality that will benefit from the expertise of both parties.

As a result of a 2008 agreement, USP and the Chinese Pharmacopoeia Commission (ChP) agreed this week to jointly develop standards for active pharmaceutical ingredients that have been singled out by the U.S. FDA and China State Food and Drug Administration (SFDA) as being especially important to help ensure quality medicines for patients and practitioners.

Date: June 19, 2009
Source United States Pharmacopeial Convention 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE